Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients.
Published
Journal Article
We investigated the emergence of cytomegalovirus (CMV) ganciclovir-resistance mutations in 301 high-risk solid-organ transplant (SOT) recipients after oral prophylaxis, for 100 days, with either valganciclovir or ganciclovir. For patients treated with ganciclovir, the incidence of CMV UL97 mutations was 1.9% (2/103) at the end of prophylaxis and 6.1% (2/33) for patients with suspected CMV disease up to 1 year after transplantation. No resistance mutations were detected in samples from valganciclovir-treated patients. Dual polymerase (UL54) and UL97 resistance mutations were not seen. Valganciclovir was associated with negligible risk of resistance and thus constitutes a useful alternative to ganciclovir prophylaxis for CMV in high-risk SOT recipients.
Full Text
Duke Authors
Cited Authors
- Boivin, G; Goyette, N; Gilbert, C; Roberts, N; Macey, K; Paya, C; Pescovitz, MD; Humar, A; Dominguez, E; Washburn, K; Blumberg, E; Alexander, B; Freeman, R; Heaton, N; Covington, E
Published Date
- May 1, 2004
Published In
Volume / Issue
- 189 / 9
Start / End Page
- 1615 - 1618
PubMed ID
- 15116297
Pubmed Central ID
- 15116297
International Standard Serial Number (ISSN)
- 0022-1899
Digital Object Identifier (DOI)
- 10.1086/382753
Language
- eng
Conference Location
- United States